Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Change in Receivables (2016 - 2025)

Conmed (CNMD) has disclosed Change in Receivables for 16 consecutive years, with $22.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 82.83% year-over-year to $22.7 million, compared with a TTM value of $2.4 million through Dec 2025, up 45.83%, and an annual FY2025 reading of $2.4 million, up 45.83% over the prior year.
  • Change in Receivables was $22.7 million for Q4 2025 at Conmed, up from -$9.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $22.7 million in Q4 2025 and bottomed at -$19.0 million in Q1 2025.
  • Average Change in Receivables over 5 years is $3.3 million, with a median of $1.9 million recorded in 2023.
  • The sharpest move saw Change in Receivables skyrocketed 12578.53% in 2023, then tumbled 2190.75% in 2025.
  • Year by year, Change in Receivables stood at $19.0 million in 2021, then crashed by 157.16% to -$10.9 million in 2022, then soared by 183.14% to $9.1 million in 2023, then surged by 36.97% to $12.4 million in 2024, then soared by 82.83% to $22.7 million in 2025.
  • Business Quant data shows Change in Receivables for CNMD at $22.7 million in Q4 2025, -$9.2 million in Q3 2025, and $7.8 million in Q2 2025.